Segment Information (Tables)

6 Months Ended

Jun. 27, 2025

Segment Reporting [Abstract]

Revenue, Gross Profit, Gross Profit Margin, Operating Income (Loss), and Depreciation and Amortization Expenses by Reportable Segment

	Three Months Ended June 27, 2025							Six Months Ended June 27, 2025
	Automation Enabling Technologies		Medical Solutions		Total			Automation Enabling Technologies			Medical Solutions		Total
Revenue	$	121,672	$	119,377	$	241,049		$	244,839		$	229,576	$	474,415
Cost of revenue		62,136		66,973					124,559			129,009
Amortization of purchased intangible assets		1,330		2,890					2,689			5,092
Segment gross profit		58,206		49,514		107,720			117,591			95,475		213,066
Research and development and engineering		9,269		16,169					18,708			30,125
Selling, general and administrative		18,331		15,064					37,489			29,794
Amortization of purchased intangible assets		2,347		4,524					4,755			7,670
Restructuring, acquisition, and related costs		1,385		7,132					(1,724	)		7,232
Segment operating income		26,874		6,625		33,499			58,363			20,654		79,017
Unallocated costs		—		—		(18,588	)		—			—		(31,685	)
Interest income (expense), net		—		—		(5,815	)		—			—		(11,459	)
Other income (expense), net		—		—		(3,307	)		—			—		(3,666	)
Income before income taxes	$	26,874	$	6,625	$	5,789		$	58,363		$	20,654	$	32,207

	Three Months Ended June 28, 2024							Six Months Ended June 28, 2024
	Automation Enabling Technologies		Medical Solutions		Total			Automation Enabling Technologies		Medical Solutions		Total
Revenue	$	116,729	$	119,135	$	235,864		$	234,118	$	232,662	$	466,780
Cost of revenue		60,168		67,679					120,485		132,862
Amortization of purchased intangible assets		1,566		2,119					3,136		4,241
Segment gross profit		54,995		49,337		104,332			110,497		95,559		206,056
Research and development and engineering		9,977		13,901					19,974		27,167
Selling, general and administrative		18,893		12,815					37,388		26,437
Amortization of purchased intangible assets		2,796		4,111					5,597		7,060
Restructuring, acquisition, and related costs		1,810		361					2,089		727
Segment operating income		21,519		18,149		39,668			45,449		34,168		79,617
Unallocated costs		—		—		(13,953	)		—		—		(28,295	)
Interest income (expense), net		—		—		(8,266	)		—		—		(16,520	)
Other income (expense), net		—		—		(319	)		—		—		(756	)
Income before income taxes	$	21,519	$	18,149	$	17,130		$	45,449	$	34,168	$	34,046

	Three Months Ended				Six Months Ended
	June 27,		June 28,		June 27,		June 28,
Depreciation and Amortization Expenses	2025		2024		2025		2024
Automation Enabling Technologies	$	5,445	$	5,869	$	10,921	$	11,725
Medical Solutions		9,745		7,813		17,424		14,410
Unallocated		391		434		799		910
Total	$	15,581	$	14,116	$	29,144	$	27,045

	June 27,		December 31,
	2025		2024
Accounts Receivable
Automation Enabling Technologies	$	66,164	$	70,829
Medical Solutions		95,038		80,197
Total accounts receivable	$	161,202	$	151,026
Inventories
Automation Enabling Technologies	$	96,046	$	89,009
Medical Solutions		72,019		55,597
Total inventories	$	168,065	$	144,606
Total segment assets	$	329,267	$	295,632

Schedule of Geographic Revenue

The Company aggregates geographic revenue based on the customer locations where products are shipped to. Revenue by geography was as follows (in thousands):

	Three Months Ended				Six Months Ended
	June 27,		June 28,		June 27,		June 28,
	2025		2024		2025		2024
United States	$	128,118	$	123,391	$	251,764	$	240,472
Germany		27,258		31,919		55,735		65,100
Rest of Europe		34,847		32,528		66,628		63,499
China		21,777		19,014		43,211		36,085
Rest of Asia-Pacific		24,667		25,334		48,046		52,590
Other		4,382		3,678		9,031		9,034
Total	$	241,049	$	235,864	$	474,415	$	466,780

Revenue By End Market

The Company primarily operates in two end markets: the medical market and the advanced industrial market. Revenue by end market was approximately as follows:

	Three Months Ended						Six Months Ended
	June 27,			June 28,			June 27,			June 28,
	2025			2024			2025			2024
Medical		54	%		58	%		54	%		57	%
Advanced Industrial		46	%		42	%		46	%		43	%
Total		100	%		100	%		100	%		100	%